



FROM VISION 2020 TO FUTURE PERSPECTIVES

DISEASE DIAGNOSTICS AND THERAPY


Thursday, June 6, 2019, 17:00h
Lecture Hall Y03 G91
University of Zurich, Irchel Campus
Janine Hähnlein,
PhD, Scientist AD&QC, Kiadis, The Netherlands



Kiadis Pharma and ATIR101 in personalized leukemia therapy

During my presentation, I will introduce Kiadis and their lead product ATIR101. ATIR is a personalized therapeutic to support patients after high-risk hematopoietic stem cell transplantation (HSCT). Since the bone marrow is completely destroyed for HSCT, the patients become highly vulnerable to infections and disease relapse. In ATIR101, T cells that cause graft-versus-host-disease (GVHD) are depleted, while functional T cells that kill cancer cells and fight infections are retained. I will talk about my current position in Assay Development and about my personal experiences working in academia and for a pharmaceutical company.

The presentation is followed by an aperitif and - for a limited number of students - by a dinner with the speaker. For the dinner, contact amalia.ruizserrano@uzh.ch not later than May 31, 2019 by explaining why you would like to meet the speaker.



Organization

The event series From Vision 2020 to Future Perspectives is organized by a committee of PhD students of the PhD Program in Integrative Molecular Medicine (imMed):
Institute of Physiology UZH: Tobias Hasler (chair) | Amalia Ruiz Serrano (chair)
Sophie Dahl | Ilaria Orlando
Institute of Physiology UZH: Elisabetta Biglieri | Merel van Gogh from the PhD Program Cancer Biology
URPP Global Change and Biodiversity: Maria Parreño
Supported by the SUK Program "Doktoratsprogramme".